We are a small molecule therapeutics focused biotech with additional novel payload technology for drug conjugates (XDC). In late 2021, we spun off from Global Health Drug Discovery Institute (GHDDI), a non-profit research organization funded by the Gates Foundation. Our leading asset is a novel oral broad spectrum nucleotide monophosphate prodrug against vRdRp. We are conducting IND enabling studies to develop multiple antiviral product combinations not only for upper respiratory viral infections but also animal health applications. Meanwhile, we are also advancing two epigenetic modulator programs with preclinical candidates for immunooncology and protein degradation against solid tumors seperately. Over the past 2 years, we also developed next generation novel payload technology for drug conjugates (XDC) for collaboration.